Indiana Attorney General Sues Eli Lilly Over Insulin Prices
STATEWIDE—Indiana Attorney General Todd Rokita is taking legal action against Eli Lilly and Company to lower insulin prices and improve healthcare affordability for Hoosiers.
Rokita accuses Eli Lilly of participating in a scheme with other insulin manufacturers and pharmacy benefit managers to artificially inflate insulin prices by over 1000% despite low manufacturing costs.
“This action aims to drive structural market changes, provide relief to affected consumers, and ensure lasting accountability,” said Rokita.
The attorney general’s office says almost 700,000 Hoosiers have been diagnosed with diabetes, with millions more being pre-diabetic.
“Pharmaceutical companies should not take advantage of Hoosiers or any other American—this includes Lilly, regardless of its Indiana roots,” Rokita argued.
Indiana joins states like Texas, California, Minnesota and Michigan that are suing Lilly, which recently became the first American drug-maker valued more than $1 trillion, and other drug manufacturers over the price of insulin in recent years.
A Lilly spokesperson has responded with the following statement:
“It is unfortunate that the Indiana AG would decide to spend state resources on such a wasteful lawsuit and sue an Indiana company that has led the way in making insulin more affordable for Americans. Similar cases by other plaintiffs have either been dismissed, dropped or settled for no money after years of costly litigation.
Lilly is confident in the strength of our legal position and we are proud of our strong record of insulin affordability solutions that have made a real impact for Hoosiers and all Americans. Lilly was the first company to cap what patients pay at $35 per month for all our insulins, we cut insulin prices by 70%, and in 2024 the average monthly out-of-pocket cost for Lilly insulin was less than $15. Years before any AG filed an insulin pricing lawsuit, Lilly collaborated with the federal government to pave the way for lower Medicare insulin prices. In addition, since 2020, Lilly has committed more than $50 billion in U.S. manufacturing investment, including $13.5 billion in Indiana, to create high-wage, advanced manufacturing, engineering and science jobs for American families.”
